MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm

Life Sci. 2020 Jul 15:253:117659. doi: 10.1016/j.lfs.2020.117659. Epub 2020 Apr 10.

Abstract

Abdominal aortic aneurysm (AAA) is a chronic vascular degenerative disease featured by progressive dilation and remodeling of the vascular wall, which may lead to aortic rupture and high mortality. The occurrence and development of AAA involve multiple mechanisms, including extracellular matrix degradation, chronic inflammation, oxidative stress, apoptosis of vascular smooth muscle cells and innate immunity. Extracellular matrix degradation is considered as the most important mechanism causing AAA. Matrix metalloproteinases (MMPs) are key factors in this process, contributing greatly to the occurrence and development of AAA. But whether the zinc-dependent endopeptidases (ADAM/ADAMTS) are involved in this process is very little known. This study is a review about the role of MMPs and ADAM/ADAMT as well as the existing MMP inhibitors in abdominal aortic aneurysm, with the purpose of providing reference for the clinical treatment of abdominal aortic aneurysm.

Keywords: ADAM/ADAMTS inhibitors; Abdominal aortic aneurysm; Matrix metalloproteinase inhibitors.

Publication types

  • Review

MeSH terms

  • ADAM Proteins / metabolism*
  • Animals
  • Aortic Aneurysm, Abdominal / drug therapy*
  • Endopeptidases / metabolism
  • Humans
  • Matrix Metalloproteinase Inhibitors / pharmacology*
  • Matrix Metalloproteinases / metabolism*
  • Myocytes, Smooth Muscle / cytology
  • Proteolysis
  • Signal Transduction

Substances

  • Matrix Metalloproteinase Inhibitors
  • Endopeptidases
  • ADAM Proteins
  • Matrix Metalloproteinases